Actively Recruiting
Evaluating Multiple Drug Combinations for Metastatic or Locally Advanced Breast Cancer A Phase IbII Randomized Study
Led by Hoffmann-La Roche · Updated on 2026-10-09
1132
Participants Needed
55
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating multiple treatment combinations for people with metastatic or inoperable locally advanced breast cancer. This umbrella study includes several patient groups based on cancer type and prior treatments. The goal is to assess the safety and effectiveness of these combinations in different breast cancer subtypes, including triple-negative, hormone receptor-positive, and HER2-positive or HER2-low disease. Participants are assigned to various treatment arms depending on their cohort. Treatments include combinations of drugs such as atezolizumab, nab-paclitaxel, capecitabine, ipatasertib, and trastuzumab deruxtecan, among others. Some participants may continue to a second treatment stage if their cancer progresses or if side effects occur, provided they meet specific criteria. During the study, participants will have regular assessments including tumor measurements, biopsies for biomarker analysis, and lab tests to monitor health and treatment effects. Researchers will measure outcomes like the tumor response rate, progression-free survival, overall survival, and side effects over up to 12 years. Participants are monitored closely to track safety and treatment impact throughout the study.
CONDITIONS
Brief Title
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Research Team
R
Reference Study ID Number: CO40115 https://forpatients.roche.com/ No attachments to email below.
F
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here